List view / Grid view
According to a new study, a metabolic enzyme studied in cancer biology is key for T-cell function, offering a novel target for anti-inflammatory therapeutics. Dr Jeffrey Rathmell and Ayaka Sugiura from Vanderbilt University in the US discuss their study with Drug Target Review and why inhibiting or genetically deleting the…
Boosting dendritic cells prevented immunotherapy resistance in mouse models, suggesting a new approach to colorectal cancer therapies.
RGX-202 was found to foil a key pathway that cancer cells rely on for energy in mice, presenting a possible new colorectal cancer therapy.
A nanotherapeutic delivery system displayed high efficacy against metastatic tumours in mice, potentially improving chemotherapy treatments.
Researchers created their new method to analyse chromosomes in 3D, revealing how misconfigurations play a role in cancer.
Having synthesised the curcusone D compound, researchers demonstrated its promise as the first BRAT1 inhibitor, making it a potential cancer therapy.
Researchers have found that colorectal cancer-associated fibroblasts can be altered using a gremlin 1-neutralising antibody or by overexpressing meflin.
Drs Sam Cooper and Michael Briskin of Phenomic AI, discuss how artificial intelligence (AI) is enabling them to target multi-cellular interactions, such as those in the tumour stroma, for drug development.
Researchers have discovered that Importin-11, a cell nucleus import protein, is required for colorectal cancer growth and may be a possible target for new therapies.
Researchers have found that PGE2, a signalling molecule involved in inflammation, promotes colorectal cancer progression through a microRNA and targeting that microRNA could have therapeutic potential.
We are on the precipice of realising the true potential of genomics studies. Following completion of the Human Genome Project six years ago, huge strides have been made in understanding how the genome works, shedding light on disease pathogenesis and forging therapeutic efforts. In this article, Pushpanathan Muthuirulan explains how…
A study has found that signals from interferons can be blocked, allowing the immune system to attack tumours which provides a potential target.
IGF-1 activated by p38 may be a therapeutic target
A CAR-T-based immunotherapy successfully kills tumours and prevents metastatic growth, in final preclinical tests before human trials...